Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 2/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.30 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.30 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5229959 | 0.95 | CACNA1H (0.33) | NPC1MAOBBCHEMAOAACHE | |
| SCHEMBL5226637 | 0.92 | MAPK1 (0.34) | HDAC3HDAC1HDAC2MAOAACHE | |
| SCHEMBL5227480 | 0.87 | MAPK1 (0.33) | MAOAACHEADRB2ADRB1HTR7 | |
| SCHEMBL5230836 | 0.86 | CHRM2 (0.34) | NPC1BCHEMAOAACHEADRB2 | |
| SCHEMBL5229143 | 0.83 | NPC1 (0.37) | NPC1 | |
| SCHEMBL4692914 | 0.81 | ADRB2 (0.30) | ADRB2ADRB1 | |
| SCHEMBL5227049 | 0.81 | CYP1A2 (0.34) | NPC1BCHEMAOAACHEADRB2 | |
| SCHEMBL6332156 | 0.79 | CACNA1H (0.35) | HDAC3HDAC1HDAC2MAOBBCHE | |
| SCHEMBL4692174 | 0.77 | CACNA1H (0.32) | CACNA1HCACNA1B | |
| SCHEMBL5227319 | 0.75 | NPC1 (0.36) | NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7312203-B2 | 1-aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | GlaxoSmithKline istraziva{hacek over (c)}ki Centar Zagreb d.o.o. (HR) | 2007-12-25 | — | — | US | claimed |
| EP-1506202-B1 | 1-AZA-DIBENZOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PREPARATION THEREOF | GLAXOSMITHKLINE ZAGREB (HR) | 2007-08-08 | — | — | EP | claimed |
| US-20070111968-A1 | 1-Aza-dibenzo[e,h]azulenes for the treatment of central nervous system diseases and disorders | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) | 2007-05-17 | — | — | US | claimed |
| US-20050209191-A1 | 1-Aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-09-22 | — | — | US | claimed |
| US-20050148578-A1 | 1-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-07-07 | — | — | US | claimed |
| US-7312203-B2 | 1-aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | GlaxoSmithKline istraziva{hacek over (c)}ki Centar Zagreb d.o.o. (HR) | 2007-12-25 | — | — | US | disclosed |
| EP-1506202-B1 | 1-AZA-DIBENZOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PREPARATION THEREOF | GLAXOSMITHKLINE ZAGREB (HR) | 2007-08-08 | — | — | EP | disclosed |
| US-20070111968-A1 | 1-Aza-dibenzo[e,h]azulenes for the treatment of central nervous system diseases and disorders | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) | 2007-05-17 | — | — | US | disclosed |
| US-20050209191-A1 | 1-Aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-09-22 | — | — | US | disclosed |
| US-20050148578-A1 | 1-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111968-A1 | 1-Aza-dibenzo[e,h]azulenes for the treatment of central nervous system diseases and disorders | DBH, BCHE, DDT | NPC1 812/4885HDAC3 1863/4885HDAC1 1013/4885 |
| US-20050209191-A1 | 1-Aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | TNF, IL1A, IL1B | NPC1 3522/4885HDAC3 3136/4885HDAC1 783/4885 |
| US-20050148578-A1 | 1-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof | TNF, IL1A, IL1B | NPC1 3480/4885HDAC3 3087/4885HDAC1 743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.